PMID- 12025233
OWN - NLM
STAT- MEDLINE
DCOM- 20020605
LR  - 20190916
IS  - 0735-7907 (Print)
IS  - 0735-7907 (Linking)
VI  - 20
IP  - 3
DP  - 2002
TI  - Applications of SKY in cancer cytogenetics.
PG  - 373-86
AB  - Clinical and cancer cytogenetics is a rapidly evolving discipline. The past 
      decade has seen a dramatic change in molecular biology and fluorescence 
      microscopy. The use of fluorescence in situ hybridization (FISH) technologies has 
      enabled the rapid analysis of cytogenetic specimens as an adjunct to classical 
      cytogenetic analysis. Spectral karyotyping (SKY) is a 24-color, multi-chromosomal 
      painting assay that allows the visualization of all human chromosomes in one 
      experiment. The ability for SKY analysis to detect equivocal or complex 
      chromosomal rearrangements, as well as to identify the chromosomal origins of 
      marker chromosomes and other extra-chromosomal structures, makes this a highly 
      sensitive and valuable tool for identifying recurrent chromosomal aberrations. 
      The SKY has been applied to various tumor groups including hematological 
      malignancies, sarcomas, carcinomas and brain tumors, with the intent of 
      identifying specific chromosomal abnormalities that may provide insight to the 
      genes involved in the disease process as well as identifying recurrent 
      cytogenetic markers for clinical diagnosis and prognostic assessment. The SKY has 
      also been applied for the mouse genome, enabling investigators to extrapolate 
      information from mouse models of cancer to their human counterparts. This review 
      will address the advances that SKY has facilitated in the field of cancer 
      cytogenetics, as well as its variety of application in the cancer research 
      laboratories.
FAU - Bayani, Jane M
AU  - Bayani JM
AD  - Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, 
      Ontario, Toronto, Canada M5G 2M9.
FAU - Squire, Jeremy A
AU  - Squire JA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cancer Invest
JT  - Cancer investigation
JID - 8307154
RN  - 0 (Genetic Markers)
SB  - IM
MH  - *Chromosome Aberrations
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karyotyping/methods
MH  - Molecular Biology/methods
MH  - Neoplasms/*genetics
MH  - Sensitivity and Specificity
RF  - 101
EDAT- 2002/05/25 10:00
MHDA- 2002/06/06 10:01
CRDT- 2002/05/25 10:00
PHST- 2002/05/25 10:00 [pubmed]
PHST- 2002/06/06 10:01 [medline]
PHST- 2002/05/25 10:00 [entrez]
AID - 10.1081/cnv-120001183 [doi]
PST - ppublish
SO  - Cancer Invest. 2002;20(3):373-86. doi: 10.1081/cnv-120001183.